{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:02:47Z","timestamp":1786993367956,"version":"build-2736575974"},"reference-count":8,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T19:37:03Z","timestamp":1563478623000},"page":"104286","source":"Crossref","is-referenced-by-count":48,"title":["Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report"],"prefix":"10.1016","volume":"28","author":[{"given":"Stephen","family":"Aradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0001","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.npep.2013.10.010","article-title":"CGRP and migraine: could PACAP play a role too?","volume":"47","author":"Kaiser","year":"2013","journal-title":"Neuropeptides"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0002","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","article-title":"Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects","volume":"34","author":"Vu","year":"2017","journal-title":"Pharm Res"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0003","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1474-4422(13)70067-X","article-title":"Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study","volume":"12","author":"Amin","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0004","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0333102414550416","article-title":"Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies","volume":"35","author":"Roberto","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0005","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0006","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.0000000000004391","article-title":"Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study","volume":"89","author":"Ashina","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0007","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","volume":"13","author":"Dodick","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.07.002_bib0008","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jamaneurol.2018.1268","article-title":"Who should try new antibody treatments for migraine?","volume":"75","author":"Loder","year":"2018","journal-title":"JAMA Neurol"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305719303271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305719303271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T11:17:49Z","timestamp":1569323869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305719303271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1052305719303271"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2019.07.002","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"article-number":"104286"}}